VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma

European Journal of Endocrinology

Volumn 164, Issue 2, 2011, Pages 277-284

  Karaca, Z ^a   Tanriverdi, F ^a   Unluhizarci, K ^a   Ozturk, F ^a   Gokahmetoglu, S ^a   Elbuken, G ^a   Cakir, I ^a   Bayram, F ^a   Kelestimur, F ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; NODULAR GOITER; OPERATION DURATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THYROID CARCINOMA; THYROIDECTOMY; DISEASE DURATION; DISEASE MARKER; DISTANT METASTASIS; FOLLOW UP; HISTOPATHOLOGY; MAJOR CLINICAL STUDY; TISSUE CHARACTERIZATION; TUMOR DIFFERENTIATION;

ADULT; AGED; ANALYSIS OF VARIANCE; CARCINOMA, PAPILLARY; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; STATISTICS, NONPARAMETRIC; THYROID NEOPLASMS; THYROIDECTOMY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 78751551676     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0967     Document Type: Article

References (47)

1. Kerbel RS. Tumor angiogenesis. New England Journal of Medicine 2008 358 2039-2049. (doi:10.1056/NEJMra0706596)
2. Shibuya M & Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Experimental Cell Research 2006 312 549-560. (doi:10.1016/j.yexcr.2005.11.012)
3. Bunone G, Vigneri P, Mariani L, Butó S, Collini P, Pilotti S, Pierotti MA & Bongarzone I. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. American Journal of Pathology 1999 155 1967-1976.
4. Klein M, Picard E, Vignaud JM, Marie B, Bresler L, Toussaint B, Weryha G, Duprez A & Leclère J. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. Journal of Endocrinology 1999 161 41-49. (doi:10.1677/joe.0.1610041)
5. Sato K. Vascular endothelial growth factors and thyroid disorders. Endocrine Journal 2001 48 635-646. (doi:10.1507/endocrj.48.635)
6. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE & Clark OH. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. Journal of Clinical Endocrinology and Metabolism 1997 82 3741-3747. (doi:10.1210/jc.82.11.3741)
7. Tuttle RM, Fleisher M, Francis GL & Robbins RJ. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. Journal of Clinical Endocrinology and Metabolism 2002 87 1737-1742. (doi:10.1210/jc.87.4. 1737) (Pubitemid 34615263)
8. Poulaki V, Mitsiades CS, McMullan C, Sykoutri D, Fanourakis G, Kotoula V, Tseleni-Balafouta S, Koutras DA & Mitsiades N. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 2003 88 5392-5398. (doi:10.1210/jc.2003-030389)
9. Gydee H, O'Neill JT, Patel A, Bauer AJ, Tuttle RM & Francis GL. Differentiated thyroid carcinomas from children and adolescents express IGF-I and the IGF-I receptor (IGF-I-R). Cancers with the most intense IGF-I-R expression may be more aggressive. Pediatric Research 2004 55 709-715. (doi:10.1203/01.PDR.0000111282.98401.93)
10. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G, Fusco A & Persico MG. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 1995 11 1569-1579.
11. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plénat F, Leclère J, Duprez A & Weryha G. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma 15. Journal of Clinical Endocrinology and Metabolism 2001 86 656-658. (doi:10.1210/jc.86.2.656)
12. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, Blair E, Francis GL & Tuttle RM. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer 14. Surgery 2001 129 552-558. (doi:10.1067/msy.2001.112592)
13. Kilicarslan AB, Ogus M, Arici C, Pestereli HE, Cakir M & Karpuzoglu G. Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica 2003 111 439-443. (doi:10.1034/j.1600-0463.2003.t01-1- 1110209.x)
14. Fenton C, Patel A, Dinauer C, Robie DK, Tuttle RM & Francis GL. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 2000 10 349-357. (doi:10.1089/thy.2000.10.349)
15. de la Torre NG, Buley I, Wass JA & Turner HE. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour 10. Endocrine-Related Cancer 2006 13 931-944. (doi:10.1677/erc.1.01210)
16. Vieira JM, Santos SC, Espadinha C, Correia I, Vag T, Casalou C, Cavaco BM, Catarino AL, Dias S & Leite V. Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. European Journal of Endocrinology 2005 153 701-709. (doi:10.1530/eje.1.02009)
17. Lin JD. Papillary thyroid carcinoma with lymph node metastases 5. Growth Factors 2007 25 41-49. (doi:10.1080/08977190601000095)
18. Hung CJ, Ginzinger DG, Zarnegar R, Kanauchi H, Wong MG, Kebebew E, Clark OH & Duh QY. Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors 13. Journal of Clinical Endocrinology and Metabolism 2003 88 3694-3699. (doi:10.1210/jc.2003-030080)
19. Siironen P, Ristimäki A, Narko K, Nordling S, Louhimo J, Andersson S, Haapiainen R & Haglund C. VEGF-C and COX-2 expression in papillary thyroid cancer 12. Endocrine-Related Cancer 2006 13 465-473. (doi:10.1677/erc.1.01114)
20. Tian X, Cong M, Zhou W, Zhu J & Liu Q. Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer. Journal of International Medical Research 2008 36 699-703.
21. Yasuoka H, Nakamura Y, Zuo H, Tang W, Takamura Y, Miyauchi A, Nakamura M, Mori I & Kakudo K. VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Modern Pathology 2005 18 1127-1133. (doi:10.1038/modpathol.3800402)
22. Dumont JE, Lamy F, Roger P & Maenhaut C. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiological Reviews 1992 72 667-697.
23. Milazzo G, La Rosa GL, Catalfamo R, Vigneri R & Belfiore A. Effect of TSH in human thyroid cells: evidence for both mitogenic and antimitogenic effects. Journal of Cellular Biochemistry 1992 49 231-238. (doi:10.1002/jcb. 240490305)
24. van der Laan BF, Freeman JL & Asa SL. Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues 20. Thyroid 1995 5 67-73. (doi:10.1089/thy.1995.5.67)
25. Vannelli GB, Barni T, Modigliani U, Paulin I, Serio M, Maggi M, Fiorelli G & Balboni GC. Insulin-like growth factor-I receptors in nonfunctioning thyroid nodules. Journal of Clinical Endocrinology and Metabolism 1990 71 1175-1182. (doi:10.1210/jcem-71-5-1175) (Pubitemid 20386315)
26. Belfiore A, Pandini G, Vella V, Squatrito S & Vigneri R. Insulin/IGFI hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie 1999 81 403-407. (doi:10.1016/S0300-9084(99)80088-1)
27. Silva Filho GB, Maciel RM, Takahashi MH, Alberti VN, Castro IV, Saldiva PH, Durazzo MD & Ferraz AR. Study of immunohistochemical expression of insulin-like growth factor I and proliferating cell nuclear antigen in thyroid gland papillary carcinoma and its metastasis. Head & Neck 1999 21 723-727. (doi:10.1002/(SICI)1097-0347(199912)21:8!723::AID-HED7O3.0.CO;2-6)
28. Yashiro T, Ohba Y, Murakami H, Obara T, Tsushima T, Fujimoto Y, Shizume K & Ito K. Expression of insulin-like growth factor receptors in primary human thyroid neoplasms. Acta Endocrinologica 1989 121 112-120. (doi:10.1530/acta.0.1210112)
29. Maiorano E, Ciampolillo A, Viale G, Maisonneuve P, Ambrosi A, Triggiani V, Marra E & Perlino E. Insulin-like growth factor 1 expression in thyroid tumors. Applied Immunohistochemistry and Molecular Morphology 2000 8 110-119. (doi:10.1097/00022744-200006000-00005)
30. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T, Rubin R, Efstratiadis A & Baserga R. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Molecular and Cellular Biology 1994 14 3604-3612.
31. Yu XM, Lo CY, Lam AK, Leung P & Luk JM. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Annals of Surgery 2008 247 483-489. (doi:10.1097/SLA.0b013e31815fa447)
32. Klubo-Gwiezdzinska J, Junik R, Kopczynska E, Juraniec O & Kardymowicz H. The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter. European Journal of Endocrinology 2007 157 521-527. (doi:10.1530/EJE-07-0252)
33. Lin SY,Wang YY & Sheu WH. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer. Clinical Endocrinology 2003 58 513-518. (doi:10.1046/j.1365-2265.2003.01749.x)
34. Yu XM, Lo CY, Lam AK, Lang BH, Leung P & Luk JM. The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. Surgery 2008 144 934-940. (doi:10.1016/j.surg.2008.07.027)
35. Hedayati M, Kolomecki K, Pasieka Z, Korzeniowska M & Kuzdak K. Assessment of VEGF and VEGF receptor concentrations in patients with benign and malignant thyroid tumors. Endokrynologia Polska 2005 56 252-258.
36. Clement S, Refetoff S, Robaye B, Dumont JE & Schurmans S. Low TSH requirement and goiter in transgenic mice overexpressing IGF-I and IGF-IR receptor in the thyroid gland. Endocrinology 2001 142 5131-5139. (doi:10.1210/en.142.12.5131) (Pubitemid 33131939)
37. Kimura T, Dumont JE, Fusco A & Golstein J. Insulin and TSH promote growth in size of PC Cl3 rat thyroid cells, possibly via a pathway different from DNA synthesis: comparison with FRTL-5 cells. European Journal of Endocrinology 1999 140 94-103. (doi:10.1530/eje.0.1400094)
38. Bogazzi F, Manetti L, Bartalena L, Gasperi M, Grasso L, Cecconi E, Rago T, Pinchera A & Martino E. Thyroid vascularity is increased in patients with active acromegaly. Clinical Endocrinology 2002 57 65-70. (doi:10.1046/j.1365- 2265.2002.01562.x)
39. Cheung NW & Boyages SC. The thyroid gland in acromegaly: an ultrasonographic study. Clinical Endocrinology 1997 46 545-549. (doi:10.1046/j.1365-2265.1997.1680985.x)
40. Cheung NW & Boyages SC. Increased incidence of neoplasia in females with acromegaly. Clinical Endocrinology 1997 47 323-327. (doi:10.1046/j.1365- 2265.1997.2561053.x)
41. Gasperi M, Martino E, Manetti L, Arosio M, Porretti S, Faglia G, Mariotti S, Colao AM, Lombardi G, Baldelli R, Camanni F, Liuzzi A & Acromegaly Study Group of the Italian Society of Endocrinology. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. Journal of Endocrinological Investigation 2002 25 240-245.
42. Balkany C & CushingGW. An association between acromegaly and thyroid carcinoma. Thyroid 1995 5 47-50. (doi:10.1089/thy.1995.5.47)
43. Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, Olsen JH, Baron JA & Fraumeni JF Jr. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes and Control 2002 13 395-400. (doi:10.1023/A:1015713732717)
44. Tita P, Ambrosio MR, Scollo C, Carta A, Gangemi P, Bondanelli M, Vigneri R, degli Uberti EC & Pezzino V. High prevalence of differentiated thyroid carcinoma in acromegaly.ClinicalEndocrinology 2005 63 161-167. (doi:10.1111/j.1365-2265.2005.02316.x)
45. Maiorano E, Ambrosi A, Giorgino R, Fersini M, Pollice L & Ciampolillo A. Insulin-like growth factor 1 (IGF-1) in multinodular goiters: a possible pathogenetic factor. Pathology, Research and Practice 1994 190 1012-1016.
46. Minuto F, Barreca A, Del Monte P, Cariola G, Torre GC & Giordano G. Immunoreactive insulin-like growth factor I (IGF-I) and IGF-I-binding protein content in human thyroid tissue. Journal of Clinical Endocrinology and Metabolism 1989 68 621-626. (doi:10.1210/jcem-68-3-621)
47. Volzke H, Friedrich N, Schipf S, Haring R, Ludemann J, Nauck M, Dorr M, Brabant G &Wallaschofski H. Association between serum insulin-like growth factor-I levels and thyroid disorders in a population-based study. Journal of Clinical Endocrinology and Metabolism 2007 92 4039-4045. (doi:10.1210/jc.2007- 0816)